Search
Bopindolol
go.drugbank.com/drugs/DB08807ExperimentalBopindolol (INN) is an ester prodrug for the beta blocker pindolol.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIvacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIvacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesDeferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalDeferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesLomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). It was developed to address the significant unmet medical need i...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A SubstratesTaurochenodeoxycholic acid
go.drugbank.com/drugs/DB08833ExperimentalTaurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile. As a medication, taurochenodeoxycholic acid reduces cholesterol fo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAgmatine
go.drugbank.com/drugs/DB08838ExperimentalAgmantine is a natural metabolite of the amino acid arginine. It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpiv...
Categories: Cytochrome P-450 CYP2B6 Inhibitors, P-glycoprotein inhibitorsTeriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalTeriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specific...
Synonyms: (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidideCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated b...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates